NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction–associated steatohepatitis and compensated cirrhosis
The results support the content validity of NASH-CHECK for patients with compensated cirrhotic MASH, demonstrating that NASH-CHECK is a suitable PROM for use in clinical trials, studies, and practice for this patient population.
Authors
- Luke Vale (ORCID: https://orcid.org/0000-0001-8574-8429)
- Matthew Breckons (ORCID: https://orcid.org/0000-0003-3057-6767)
- Clifford A. Brass
- Quentin M. Anstee (ORCID: https://orcid.org/0000-0002-9518-0088)
- Arun Jayant Sanyal (ORCID: https://orcid.org/0000-0001-8682-5748)
- Maria‐Magdalena Balp (ORCID: https://orcid.org/0000-0002-8612-7680)
- Lorraine McSweeney (ORCID: https://orcid.org/0000-0003-1044-6201)
- Lynda Doward (ORCID: https://orcid.org/0000-0002-6236-469X)
- James Twiss
Institutions
- Novartis (Switzerland) (CH)
- Virginia Commonwealth University (US)
- Novartis (United States) (US)
- NIHR Newcastle Biomedical Research Centre (GB)
- Newcastle University (GB)
Publication Details
- Journal
- Journal of Patient-Reported Outcomes
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s41687-025-00881-6
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Virginia Commonwealth University
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- Novartis Pharma